Full Breakdown
FDA Launches National Priority Voucher Program to Expedite Drug Reviews
10/19/2025, 6:20:37 AM
Overview of the National Priority Voucher Program
On October 16, 2023, the U.S. Food and Drug Administration (FDA) announced the first recipients of its new Commissioner’s National Priority Voucher (CNPV) program, aimed at significantly reducing the drug review timeline from the standard 10-12 months to just one to two months. This pilot initiative, launched in June 2023, is designed to expedite the approval process for innovative treatments that address major U.S. health priorities, including public health crises, unmet medical needs, and the affordability of medications.
Selected Treatments and Their Significance
The first nine products selected for expedited review include:
- Pergoveris (Merck KGaA) for infertility
- Teplizumab (Sanofi) for type 1 diabetes
- DB-OTO (Regeneron) for congenital deafness
- RMC-6236 (Revolution Medicines) for pancreatic cancer
- Bitopertin (Disc Medicine) for porphyria
- Cytisinicline (Achieve Life Sciences) for nicotine vaping addiction
- Cenegermin-bkbj (Dompé) for blindness
- Ketamine for domestic manufacturing of a general anesthetic
- Augmentin XR for domestic production of a common antibiotic
These treatments were chosen based on their potential to meet significant national health needs and to enhance domestic drug manufacturing capabilities.
Goals and Criteria of the Program
The CNPV program aims to modernize the FDA's review process by facilitating faster evaluations of drugs that align with national priorities. FDA Commissioner Marty Makary emphasized the importance of delivering meaningful treatments that can significantly impact public health. The program also seeks to reduce regulatory risks for innovative biotech companies, potentially leading to increased investment and development in the sector.
Official Statements and Responses
In a statement, Makary noted, “One of our core goals is to deliver more cures and meaningful treatments—especially ones that have an outsized impact on our most pressing national priorities.” He highlighted the need for the FDA to move beyond a “receive-only mode” in identifying promising treatments. The FDA plans to announce a second batch of CNPV recipients in the coming months, indicating ongoing commitment to this initiative.
Criticism and Opposition
While the program has been generally well-received, some industry analysts have expressed concerns about the potential for rushed evaluations that could compromise safety. Critics argue that while expedited reviews can be beneficial, they must not sacrifice thoroughness in the approval process.
Market Reactions
Following the announcement, shares of companies like Revolution Medicines and Disc Medicine saw significant increases, reflecting investor optimism about the expedited review process and its potential to enhance market competitiveness.
What's Next
The FDA is expected to continue its efforts to streamline drug approvals through the CNPV program, with additional recipients to be announced soon. This initiative arrives amid a resurgence in the biotech sector, driven by favorable market conditions and evolving drug-pricing policies.
The National Priority Voucher program represents a strategic shift in the FDA's approach to drug evaluations, aiming to address urgent health needs while fostering innovation in the pharmaceutical industry.
